Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals’ NP001

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health’s California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS … Read more

Neuraltus Pharmaceuticals and Clinigen Group Announce Partnership to Initiate a Managed Access Program for Investigational ALS Therapy in Europe

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of drugs to treat neurodegenerative diseases, and Clinigen Group plc’s (AIM:CLIN) Idis Managed Access (MA) division announced today that the companies are partnering to initiate a Managed Access program for NP001, Neuraltus’ investigational therapy for amyotrophic lateral sclerosis (ALS).  The partnership makes the Managed Access program … Read more

Biomarker Analyses of Neuraltus Pharmaceuticals’ NP001 Phase 2 Data Demonstrate Potential for Treating ALS Patients with Systemic Inflammation

Prospective Data in ALS Patients with Elevated Levels of C-Reactive Protein Support Further Research   Secondary analyses of Neuraltus Pharmaceuticals’ Phase 2 clinical trial of its investigational treatment, NP001, for amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease), suggest that increased levels of a biomarker for systemic inflammation, C-reactive protein (CRP), may indicate which … Read more

Neuraltus Pharmaceuticals Announces Plans for Second Phase 2 Study of NP001 in ALS Using Biomarker for Enriched Patient Selection

Phase 2 study, funded by newly secured capital, expected to begin enrolling during the summer of 2016 Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, announced plans to initiate a second Phase 2 study of its investigational treatment, NP001, in patients with amyotrophic lateral sclerosis (ALS, also known … Read more

Neuraltus Pharmaceuticals Initiates Confirmatory Phase 2 Study of NP001 in Patients with Amyotrophic Lateral Sclerosis

̶  Study to evaluate safety and efficacy of NP001 in ALS patients with evidence of systemic inflammation  ̶   Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, announced today the initiation of a second Phase 2 study of its investigational treatment, NP001, in patients with amyotrophic lateral sclerosis (ALS, … Read more

Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)

Neuraltus Pharmaceuticals, Inc., a privately-held pharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases, today announced findings from a confirmatory Phase 2 study of its investigational therapy, NP001, in ALS patients with elevated levels of systemic inflammation. The study, which enrolled 138 patients, did not meet its primary or secondary endpoints, a change from … Read more